Multiple endocrine neoplasia type 1 in end-stage renal failure

被引:0
作者
Suzuki H. [1 ]
Katoh T. [1 ]
Sakuma Y. [1 ]
Takahashi M. [1 ]
Asahi K. [1 ]
Hashimoto S. [1 ]
Kosugi S. [2 ]
Suzuki S. [3 ]
Takenoshita S. [3 ]
Watanabe T. [1 ]
机构
[1] Department of Internal Medicine III, Fukushima Medical University, School of Medicine, Fukushima 960-1295
[2] Department of Laboratory Medicine, Kyoto University, School of Medicine, Kyoto
[3] Department of Surgery II, Fukushima Medical University, School of Medicine, Fukushima
来源
Journal of Clinical and Experimental Nephrology | 2004年 / 8卷 / 4期
关键词
Chronic renal failure; Menin; Parathyroid hormone;
D O I
10.1007/s10157-004-0318-7
中图分类号
学科分类号
摘要
A 59-year-old woman with chronic renal failure due to type 2 diabetes mellitus (DM) is presented. Her father and a brother had a history of brain tumor. Her blood urea nitrogen and serum creatinine levels were 102∈mg/dl and 4.5∈mg/dl, respectively. Her serum Ca2+ and Pi were within the normal range (9.4∈mg/dl and 5.4∈mg/dl, respectively). Her intact parathyroid hormone (PTH) level was 1∈730∈000∈pg/ml. A 99mTc-methoxy-isobutylisonitrile scintigraphy showed high uptake in three parathyroid glands. A magnetic resonance image showed microadenoma in the pituitary gland. The serum gastrin level was high. Genetic examination revealed a mutation of the MEN1 gene (894-9 G → A). From these findings, she was diagnosed with multiple endocrine neoplasia (MEN) type 1. Subsequently, a parathyroidectomy was performed successfully, a parathyroid gland was transplanted to her right forearm, and her serum Ca2+ level was controlled at 8.5-9.0∈mg/dl. It is very important to identify MEN1 if an end-stage renal disease (ESRD) patient has hyperparathyroidism with multigland involvement. Examination of the MEN1 gene may be valuable to make an accurate diagnosis and choose the appropriate therapy in some ESRD patients with hyperparathyroidism. © Japanese Society of Nephrology 2004.
引用
收藏
页码:380 / 383
页数:3
相关论文
共 15 条
[1]  
Llach F., Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited, Am J Kidney Dis, 25, pp. 663-679, (1995)
[2]  
Fukuda N., Tanaka H., Tominaga Y., Fukagawa M., Kurokawa K., Seino Y., Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients, J Clin Invest, 92, pp. 1436-1443, (1993)
[3]  
Kifor O., Moore F.D., Wang P., Goldstein M., Vassilev P., Kifor I., Et al., Reduced immunostaining for the extracellular Ca<sup>2+</sup>-sensing receptor in primary and uremic secondary hyperparathyroidism, J Clin Endocrinol Metab, 81, pp. 1598-1606, (1996)
[4]  
Tominaga Y., Tsuzuki T., Uchida K., Haba T., Otsuka S., Ichimori T., Et al., Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma, Kidney Int, 55, pp. 1375-1383, (1999)
[5]  
Mizumoto D., Watanabe Y., Fukuzawa Y., Aoi N., Yamazaki C., Clinical profile and outcome of primary hyperparathyroidism accompanied by chronic renal failure, Clin Nephrol, 42, pp. 315-321, (1994)
[6]  
Lawrence D.A., A histological comparison of adenomatous and hyperplastic parathyroid glands, J Clin Pathol, 31, pp. 626-632, (1978)
[7]  
Smith J.F., Parathyroid adenomas associated with the malabsorption syndrome and chronic renal disease, J Clin Pathol, 23, pp. 362-369, (1970)
[8]  
Kishi M., Tsukada T., Shimizu S., Hosono K., Ohkubo T., Kosuge T., Et al., A novel splicing mutation (894-9 G → A) of the MEN1 gene responsible for multiple endocrine neoplasia type 1, Cancer Lett, 142, pp. 105-110, (1999)
[9]  
Schussheim D.H., Skarulis M.C., Agarwal S.K., Simonds W.F., Burns A.L., Spiegel A.M., Et al., Multiple endocrine neoplasia type 1: New clinical and basic findings, Trends Endocrinol Metab, 12, pp. 173-178, (2001)
[10]  
Stratakis C.A., Clinical genetics of multiple endocrine neoplasias, Carney complex and related syndromes, J Endocrinol Invest, 24, pp. 370-383, (2001)